On December 28, 2023 Circio reported the reference is made to Circio Holding ASA’s (the "Company") stock exchange reported on 9 March 2023, in which the Company announced that it had requested Atlas Special Opportunities, LLC ("Atlas") to subscribe and pay for the first tranche of convertible bonds under the Investment Agreement entered into between Atlas and the Company, consisting of 75 convertible bonds (Press release, Circio, DEC 28, 2023, View Source [SID1234638821]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Atlas has, by a notice of conversion issued to Nordic Trustee AS, requested conversion of convertible bonds with a nominal value of NOK 500,000 which, pursuant to the bond terms, are convertible into 77,097 new shares in the Company at a conversion price of NOK 6.4853.

The Company’s share capital will accordingly be increased by NOK 46,258.20 by the issuance of 77,097 new shares upon completion of the conversion by registration of the share capital increase in the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company’s total share capital will be NOK 4,484,286.60, divided into 7,473,811 shares, each with a nominal value of NOK 0.60.